Overview:
With the development of antibody-drug conjugates and immune checkpoint inhibitors, the treatment of both adult and pediatric patients with advanced Hodgkin lymphoma (HL) is undergoing a transformation. New therapeutic targets are also emerging for patients with relapsed/refractory disease. Thus, there is a need for education regarding current and emerging novel therapeutic approaches in the management of HL.
This How We Do It® symposium will bring together clinical experts in lymphoma to highlight evolving approaches to the diagnosis and treatment of patients with HL. Evidence-based assessments of current standards of practice and the most important clinical trials will set the stage for extensive case-based discussion sessions, which will address newly diagnosed patients, relapsed/refractory disease, and pediatric patients. Additionally, strategies to maximize the safety of treatment regimens in patients with HL will be evaluated.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Develop personalized care plans for patients with HL based on patient-related factors, risk stratification and treatment history
- Explain the efficacy and safety of evolving adult and pediatric strategies for advanced HL from clinical trials, including real world evidence in multiple lines of care
- Apply proactive strategies to recognize and manage adverse events associated with the use of novel therapies for the management of adult and pediatric patients with advanced HL
- Utilize evidence to develop case-based strategies for the management of adult and pediatric patients with HL
Program Chair:
Joseph M. Connors, MD, CM
To view full profile, click on the Program Chair tab above.
